Skip to main content
. 2021 Feb 12;7:11. doi: 10.1038/s41523-021-00222-y

Fig. 1. Study-selection flow chart.

Fig. 1

1 L first line, 2 L second line, AI aromatase inhibitor, BC breast cancer, HR+ hormone receptor-positive, IPD individual patient data, n number of patients, SERD selective estrogen receptor degrader, SERM selective estrogen receptor modulator, VM visceral metastases.